Lacosamide Vivanta (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and reducing hyper‑excitability. It also binds to CRMP‑2, influencing axonal transport and further decreasing neuronal firing, which together help control seizure activity.

The specific dose of Lacosamide Vivanta is determined by the prescribing clinician based on the individual patient's condition, response, and renal or hepatic function. Dosing regimens are not standardized and must follow the prescriber’s instructions.

Lacosamide is classified as pregnancy category unknown; there are limited data on its safety during pregnancy and lactation. Clinicians should evaluate potential benefits against possible risks and consider alternative therapies when appropriate.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation and binding CRMP‑2—differs from many traditional antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents, though its safety profile and drug‑interaction potential must be considered alongside alternatives.

Lacosamide Vivanta must be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. Before administration, allow the product to reach room temperature if required, and inspect for particulate matter.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically as a slow infusion over several minutes, following the dosing instructions provided by the prescriber.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and anaphylactic or hypersensitivity reactions. Patients should be monitored for ECG changes, rash, or signs of allergic response during therapy.

Lacosamide Vivanta should be avoided in patients with known hypersensitivity to lacosamide or any excipients, and in those with significant cardiac conduction disorders (e.g., existing PR‑interval prolongation) unless closely monitored. Caution is also advised for patients with severe renal or hepatic impairment.